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The traditional antiviral assays for the determination of interferon potency are reported to have considerable variability between
andwithinassays.Althoughseveralreporter geneassaysbasedoninterferon-inducible promoteractivities havebeen reported, data
fromcomprehensivevalidationstudiesare lackingandfew studieshavebeen conducted toanalyzethevariantformsofinterferons,
which could have undesirable clinical implications. Here, a reporter gene assay employing a HEK293 cell line stably transfected
withluciferase gene under the control of interferon-stimulatedresponse element promoterwasdeveloped andvalidated. The assay
wasfoundto be moresensitive, with alarger detection rangethanthe antiviral assay.Severalcytokines tested did not interfere with
the test, suggesting the assay possesses a certain degree of selectivity. Moreover, the robustness of the assay was demonstrated by
minimal variations in the results generated by diﬀerent analysts and cell passage number (up to 52 passages). Finally, the method
was employed to analyze several interferon variants (interferon-α 2a) and we found that the aggregated form has completely lost
its potency; while a modest loss of bioactivity in oxidized interferon was observed (approx. 23%), the deamidated form essentially
retained its activity.
1.Introduction
Interferons (IFNs) are produced in response to bacterial and
viral infections, and play essential roles in host defence [1].
In addition, they have also been found to possess anticancer
and immunomodulatory eﬀects [1–4]. They are classiﬁed
based on cellular origin and on the type of receptors to
which they bind. Those classiﬁed to date include more than
10 IFN-α and a single β species (termed collectively IFN-
α/β), IFN-γ and 3 IFN-λ species. In humans and mice, the
α and β species are encoded by genes clustered in regions of
chromosomes 9 and 4 [5, 6]. IFN-α/β a r ec l a s s i ﬁ e da st y p eI
since they bind to IFN cell surface receptors type 1.Although
they have diﬀerent binding aﬃnities, they have similar
biological eﬀects. IFN-γ belongs to type II since it binds
only to type 2 receptors. Various types of cells including
dendritic cells, leukocytes, ﬁbroblasts, epithelial cells, and
macrophages, are known to produce IFN-α and IFN-β while
activated T-cells and natural killer cells have been reported
to produce IFN-γ [5, 6]. Only type I and type II IFNs have
been approved for use in humans; the 3 IFN-λ species are
newly classiﬁed [7], and have not been approved for human
therapy.
Recombinant IFNs for human therapies are produced in
mammalian cells orbacteria and have been used overthe last
decades to treat infectious and autoimmune diseases and in
the treatment of selected types of cancer [8–11]. Like many
other approved therapeutic products on the market, IFNs2 Journal of Biomedicine and Biotechnology
have undisputable therapeutic beneﬁts but are also linked to
the occurrence of adverse drug reactions (ADRs) or lack of
eﬃcacy. Therefore, it is important to determine the bioactiv-
ity orpotency of IFNpriorto its use in humans. The potency
of IFN has been determined traditionally by the antiviral
assay (AVA) [12, 13],in which theactivity ofIFNismeasured
based on its inhibitory eﬀects on viral replication. However,
AVA is inherently disadvantageous because of higher assay
variations, the requirement for working with virus in
Biosafety level-2 (BSL-2) laboratories, and the need to titrate
the virus [14–17]. In recent years, potency assays based
on IFN-inducible gene expression have been extensively
studied as a potential replacement for the traditional AVA
[13, 18]. The principle of these reporter gene assays (RGA)
is very straightforward, that is, quantitative determination
of responses to IFN treatment in indicator cell lines stably
transfected with IFN-inducible promoter driven reporter
gene products. A variety of IFN-inducible promoters have
been investigated including Mx, IFN-stimulated response
element (ISRE) or glial ﬁbrillary acidic protein (GFAP), so
have the various quantiﬁable gene products such as Beta
Galactosidase (β-Gal), chloramphenicol acetyltransferase
(CAT), Secreted Alkaline Phosphatase (SEAP) or luciferase
[14–26]. These previous studies suggest that the RGA is
generallysimplerand faster thanAVA. Yet, dataare limited in
terms of reproducibility, precision and accuracy in addition
to the absence of data from analyses of chemically modiﬁed
IFNs. Currently, the European Pharmacopoeia monograph
for IFN bulk solution requires potency determination on
the basis of tests for protection of cells against a viral
cytopathic eﬀect. Here we report the development of a
RGA based on ISRE-driven luciferase activity measurements
and subsequent validation of the assay with respect to
sensitivity, speciﬁcity, reproducibility, precision and robust-
ness in addition to the application of this assay to the
potency determination of physically or chemically modiﬁed
IFNs.
2.Materialsand Methods
2.1. IFNs and Other Cytokines. Reference reagent is used
in the validation studies, Gb23-902-531 (IFN-β)w h i c hw a s
obtained from the National Institute of Health through BEI
Resources branch of ATCC. Glo lysis buﬀer (E266A) and
Bright Glo luciferase assay reagent (E2620) were purchased
from Promega (Ottawa, ON, Canada), IL-1β (407615),
IL-2 (407623), IL-6 (407652) and TNF-α (654205) were
obtained from Calbiochem (San Jose, CA). IFN-α 2a and
2b reference standards were obtained from EDQM (Euro-
pean Directorate for the Quality of Medicines, Strasbourg,
France). Various IFN-α and IFN-β samples were kindly
provided by various manufacturers (see below). The activ-
ities of the in-house reference standards or samples used
in these designed studies were predetermined by traditional
antiviral assays using WHO standards unless otherwise
speciﬁed.
2.2. Development of Stable Cell Lines Expressing Lucifer-
ase under the Control of ISRE (HEK293-ISRE-Luc). ISRE-
Luc reporter plasmid and pIRESp2 encoding puromycin-
resistant gene (Clonetech, Mountain View, CA) (ratio 1:10)
were introduced into HEK293 cells (ATCC, Manassas, VA)
by the calcium phosphate method. Cells were selected
beginning at 48 hours after transfection for approximately 2
weeks in MEM containing 10% fetal calf serum, antibiotics,
and 2μg/mL puromycin (Sigma). Puromycin-resistant cells
were then cloned twice by limiting dilutions to select single
cellclones.Afterthattheselectedcloneswereroutinelymain-
tained in MEM in the presence of 2μg/mL ofpuromycin and
10%fetalcalfserum(Gibco,Burlington,ON).Cellpassaging
is achieved by detaching the cells in 0.25% Trypsin-EDTA
and splitting the cells every 3 days.
2.3. RGA Procedure. The procedure is comprised of three
simple steps, that is, seeding the cells in the presence of IFN
atspeciﬁedconcentrationsinto96-wellplates,followedbyan
overnightincubationoftheculturesand directmeasurement
ofluciferaseactivityinthecelllysates.Inbrief,96-wellCostar
plates were seeded with 0.04 × 106 cells in the presence of
IFN or controls in a total volume of 100μL per well. The
plate was incubated at 37◦Cw i t h5 %C O 2 for 21 hours.
The culture supernatants were then removed by aspiration
and the cells washed once with PBS, followed by addition of
70μLP r omegaGloL ysisbuﬀer.Theplatesweresubsequently
shakenfor5minutesonatitre-plateshaker(FisherScientiﬁc,
Ottawa, ON), followed by the addition of 70μLo fP r o m e g a
Bright Glo Luciferase Assay reagent. Luciferase activity was
then determined by reading on a Luminoscan Ascent plate
reader and data analysed using Combistat (see below “data
analyses”).
2.4. Matrix Interference (Selectivity). The speciﬁcity of the
RGA was determined by performing matrix interference
experiments. To this end, we used IL-2, IL-1β,I L - 6 ,a n d
TNF-α to treat the cells under the same condition as
described above for the analyses of IFN and determined
whether the presence of these cytokines could interfere with
luciferase output.
2.5. Preparation and Fractionation of Modiﬁed IFN Vari-
ants. The preparation of modiﬁed forms of human IFN
(aggregated, deamidated, or oxidized) was carried out as
described elsewhere [27] (Diress et al. unpublished data).
In brief, the aggregated forms were prepared by incubating
the samples at 37–80◦C. If samples contained precipitates
and/or a milky suspension formed during the incubation,
the precipitate was removed by centrifugation. Denaturation
and reduction of samples were carried out by incubating
IFN-α 2a sample at 25◦C in a solution containing 0.01M
sodium phosphate (pH 7.0), 6.0M guanidine hydrochloride
(GdnHCl) or 1, 4-dithiothreitol (DTT), respectively. Oxi-
dation of IFN-α 2a products was carried out according to
t h ep r o c e d u r ed e s c r i b e di nt h eE u r o p e a nP h a r m a c o p o e i a
monograph for interferon alpha-2a (2007 #26). Accord-
ingly, IFN-α 2a sample (0.1mg/mL) was incubated withJournal of Biomedicine and Biotechnology 3
0.05% (v/v) hydrogen peroxide (H2O2)a t3 7 ◦Cf r o m3t o1 8
hours. The oxidation was stopped by adding L-methionine
(12mg/mL) and incubating the sample at room temperature
for 1 hour. Deamidation was performed by incubating IFN-
α 2a (0.1mg/mL) samples in 20mM sodium phosphate (pH
8.0) or 20mM Tris-HCl (pH 8.0) buﬀers. The samples were
incubated at 37◦C for a period of one day to seven weeks.
Pure fractions containing native, aggregated, denatured and
reduced forms were collected from stock IFN-α samples
using size exclusion high performance liquid chromatog-
raphy (SE-HPLC) at room temperature as described by
us recently [27]. Oxidized and deamidated variants were
collected according to methods described elsewhere (Diress
et al. unpublished data). Fractions eluting from the HPLC
columns were collected manually based on the elution time
on the detector signal and the fractions were >85% pure.
Preparation, modiﬁcation and fraction collection of the
samples were performed under sterile conditions to avoid
contamination and growth of bacteria.
2.6. AVA for IFN Potency Determination. The antiviral ac-
tivity of IFN is used in our routine procedure for the
determination of IFN potency. In brief, WISH cells (ATCC,
Manassas, VA) were seeded in 96-well plates at a concentra-
tion of approximately 3 × 105 cells/mL (100μL per well).
T h ep l a t e sw e r ei n c u b a t e da t3 7 ◦C in the presence of 5%
CO2 for 4–6 hours. In the meantime the standards and test
samples were prepared (6 replicates for 3 replicate plates
of each dilution). The supernatants from the 96-wells were
then removed and the diluted standards and test samples
were added. The plates were incubated again for 18–24
hours. The supernatants were then removed and vesicular
stomatitis virus (VSV) was added at 100 TCID50 for an
additional incubation of 24 hours. The virus-containing
supernatants were then removed, followed by staining of
the cell layers with crystal violet staining solution (0.5mg
in 20% ethanol) for 30 minutes at room temperature. The
staining solution was then carefully aspirated. Destaining
solution (50% ethanol/0.1% acetic acid) was subsequently
pipetted into the wells and incubated for 4 minutes at room
temperature. The plates were read at 630nm/570nm in a
plate reader (Fisher Scientiﬁc, Ottawa, On). The potency of
the test sample (IU/mL) was calculated using 4-parameter
logistic (4-PL) model.
2.7. Statistical Analyses. Analyses of the data consisted of
statistical models used to calculate the relative potencies
as well as statistical techniques for method validation. In
order to calculate the relative potencies, dose response and
linear range, we used the 4-PL model (Section 5.3 of
European Pharmacopoeia Statistical Analyses of results of
the biological assays and tests). Statistical techniques for
method validation employed summary statistics such as
mean, standard deviation, coeﬃcient of variation (CV) as
well as statistical techniques such as ANOVA and conﬁdence
intervals. All statistical tests were carried out at a 5% signif-
icance level. Analyses were carried out using Combistats for
relative potency calculations and SAS for method validation.
3.Results
3.1. Response of HEK293-ISRE-Luciferase Cells to the Treat-
m e n t so fV a r i o u sT y p e so fI F N .As the assay is to be used
for potency determination of human interferon, HEK293
cells were chosen since they are of human origin. Nineteen
clonesofcellsexpressing luciferase underthe control ofISRE
were isolated and subcloned twice by limiting dilution in the
presence of puromycin (see Section 2). Eight clones were
found to be expressing high levels of luciferase activity in
response to IFN treatment in the initial screening process.
As no signiﬁcant diﬀerence was found with respect to the
responses to IFN treatment among these eight clones, one
of them was selected for further studies as the cell line for
the subsequent RGA. We ﬁrst determined how the luciferase
activity in the HEK293-ISRE-Luciferase cell clones (denoted
asHEK293-ISRE-Luc)responded tovariousformsofhuman
interferons. Type 1 IFN (α and β) was found to induce
luciferase activity in a dose-response fashion (Figure 1),
with panels (a) and (b) for IFN-β and IFN-α, respectively.
As expected, IFN-γ failed to induce detectable luciferase
activity.ForpotencyanalysisofIFN-γ,aGASelement-driven
reporter gene system should be considered [1–4, 28]. These
results are consistent with previous observations that type
I and type II IFNs exert their functional activities through
diﬀerent pathways and type I IFN is known to activate the
ISRE-driven transcription [2, 3]. We also conducted a time
course and found that the highest luciferase activity was
obtained approximately 21 hours after the IFN treatment;
the luciferase activity begins to decrease after 21–24 hours,
withsigniﬁcantdecreasedlevelsofluciferaseactivitydetected
after 48 hours (not shown). Noticeably, linear ranges for
IFN-α and β were found to be 1.5–50IU/mL and 6.25 to
200IU/mL, respectively. Given that linear range is generally
less heteroscedastic, we decided to analyze the potencies of
the IFN in this range for all subsequent experiments unless
otherwise speciﬁed (See below).
3.2. Precision
3.2.1. Intra-Assay Variation. The experiment consisted of
three replicates tested in ﬁve diﬀerent plates. Such design
made it possible to better understand the plate-to-plate
variability as well as the variation between the three samples.
The activity of the samples used in these studies were pre-
determined bytraditional antiviral assays using international
standards (see below). Respective potencies were calculated
for each plate. We then calculated summary statistics using
the obtained potencies. Our analyses resulted in a CV less
than 8% for all three samples (CV% being 6.00, 6.76, and
7.35%, resp.). These results suggest, as shown in Figure 2,
that the three lots of samples behave nearly indistinguishably
as compared with the standards.
3.2.2. Inter-Assay Variation. In order to determine the inter-
assay variation, we ran the assay on four diﬀerent days. On
each day, we performed three replicates in the same manner
as explained in the previous section. It is important to note
that the only condition changed in all assays was the day4 Journal of Biomedicine and Biotechnology
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Figure 1: HEK293-ISRE-Luc cell line responses to treatment with various types of interferons. Panel (a) represents dose response curve
obtained with IFN-β. Panel (b) represents dose response curve obtained with IFN-α. The assay was performed as described in “Section 2”.
The cells were treated with type I IFN, followed by the analyses of luciferase activity. As expected, although IFN-α and IFN-β a r eb o t ht y p eI
IFNs that drive the ISRE, the signalling pathway used is slightly diﬀerent and thus we obtain a diﬀerent dose response curve.
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Figure 2: Intra-assay variation. Three samples were used. Sample 1 was the In-House reference standard (a), with sample #2 and #3 being
ﬁnal products reconstituted from ﬁnal drug products in syringes (b, c). Each dose was run in triplicate and tested on 5 diﬀerent plates. The
graphs depict the linear range of the tested doses as determined by comparison to the NIH IFN-β standard.Journal of Biomedicine and Biotechnology 5
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Figure 3: Inter-assay variations (diﬀerent runs). Three samples were used. Sample 1 was the in-house reference standard (a), with sample
#2 and #3 being ﬁnal products (b,c). Each dose was run in triplicate and tested on 3 separate plates. The graphs represent the linear range of
the tested doses as determined by comparison to the international reference standard. The experiments were conducted on 4 diﬀerent days.
on which the assays were performed. Respective potencies
were calculated for each day. Our analyses resulted in CV
values less than 20% (2.67%, 19.09%, and 14.95%, resp.)
for all three samples, suggesting that the inter-assay variation
is negligible. In addition, ANOVA suggested no statistically
signiﬁcant day eﬀect (P-values: .273,.087, and.0685 for in-
house standard, sample 1 and sample 2, resp., against the
NIH reference standards). These ﬁndings are conﬁrmed as
presented in Figure 3.
3.2.3. The Eﬀects of Diﬀerent Analysts on the Assay. Next we
wanted to know whether there was any signiﬁcant diﬀerence
in results if the experiments were run by diﬀerent laboratory
staﬀ with no prior training for this assay. We asked four
technologists to perform the assay based on the standard
operating procedure. It is of note that the only condition
changed in all assays was the analyst (Figure 4). Respective
potencies were calculated on data generated by the four
analysts. For sample 2, we obtained CV values less than 20%
(14.6%). However, sample 1 gave us a CV value of 22.25%
suggesting that prior training should be considered if the
laboratory staﬀ is inexperienced in performing RGAs (for
more details see “Section 4”). Nevertheless, we observed no
statistically signiﬁcant diﬀerence amongst the four analysts
(P = .266 and .1816 for sample 1 and sample 2, resp.).
3.3. The Stability of the Cell Lines. In order to evaluate
the stability of cell lines, we subsequently tested how cells
respond to the IFN treatment at various passage numbers
(15,46and51,resp.).Eachcellpassagewastestedintriplicate
on three separate plates (Figure 5). CV values based on the
calculated potencies for each passage number are very small
(5.39%, 3.86%, and 6.48% resp.) which suggest that there is
no eﬀect of passage number on responsiveness to IFN in this
assay. Furthermore, results from all three samples tested in
the stability assays also support the notion that the cells are
stable (P>. 05).6 Journal of Biomedicine and Biotechnology
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Figure 4: Determination of variability in experiments conducted by 4 diﬀerent analysts. Two samples were used (both ﬁnal products of
IFN-β1a). The analysts who had no prior experiences of conducting the assay were instructed to conduct the experiments by following the
protocol. Each sample was run in triplicate and tested on 3 diﬀerent plates. The graphs represent the linear range of the tested doses as
determined by comparison to the internationalreference standard.
Table 1: Matrix interference.
LL ofestimated
potency
Estimated
potency
UL estimated
Potency
LL of relative
potency (%) Relative potency UL of relative
potency
IL-2 0.962461 1.01024 1.06045 96.2 101.00 106.00
IL-6 0.929288 0.975531 1.02393 92.9 97.60 102.40
IL-1β 0.944126 0.991046 1.04024 94.4 99.10 104.00
TNFα 1.0784 1.13208 1.18928 107.8 113.20 118.90
The table shows data from one concentration of IL-2, IL-6, IL-1β,o rT N F - α. Wider concentrations of IL-2, IL-6, IL-1β and TNF-α found no interference
with our assay (not shown in the table). The tested ranges are the following: IL-2: 200–2000IU/mL; IL-6: 200–2000IU/mL; IL-1β: 40–400U/mL; TNF-α:
100–1000ng/mL. The valuesin bold facerepresent relative potency compared with the reference standardsas determined by statisticalanalyses.LL standsfor
lower limitsof the 95% interval while UL denotes upper limits of the 95% interval.
3.4. Selectivity of HEK293-ISRE-Luc in Response to Diﬀerent
Cytokines (Matrix Interferences). Experiments were next
conducted to assess whether the presence of other cytokines
(i.e., matrix interferences) could aﬀect the expression of
luciferase activity in the HEK293-ISRE-Luc cells. Four
cytokines available in the laboratory were chosen including
IL-1β,I L - 2 ,I L - 6a n dT N F - α.T h e s ec y t o k i n e sw e r es p i k e d
into the medium along with IFN-β a n dt h e nu s e dt o
treat the cells. The potency values were compared to those
obtained with IFN-β treatment only. Asshown in Table 1,n o
interference was found with the treatments of IL-1β (950000
WHO U/mL), IL-2 (0.5μg), IL-6 (35000 WHO U/mL) or
TNF-α (5000ng/mL) as the relative potencies are close to
100% with corresponding conﬁdence intervals narrower
than80to120%.Wealsotestedwiderconcentrationsofthese
cytokines(IL-1β:40–400U/mL;IL-2:200–2000IU/mL;IL-6:
200–2000IU/mL and TNF-α: 100–1000ng/mL) and found
no signiﬁcant interference (data not shown). No study
has been conducted to measure the interference of other
cytokines.
3.5. Analyses of IFN Variants Using the RGA. Unlike drugs
derivedfromsmall molecules, therapeuticproteinsare prone
to a number of changes during preparation, formulation or
storage. These changes could involve modiﬁcations such as
oxidation, deamidation, glycosylation, isomerization, aggre-
gation, misfolding, adsorption, or precipitation [29–31].
These modiﬁcations could lead to potential loss of thera-
peutic eﬃcacy or unwanted immune reactions (i.e., ADRs).
For instance, aggregation reduces the eﬃcacy of human
calcitonin [32] whereas aggregates of IFN-α were found to
enhance immunogenicity [33, 34]. So we investigated next
whether the RGA could be used to test the potency of
modiﬁed interferon variants including oxidized, deamidated
andaggregatedforms.Tothisend,thevariants wereprepared
and puriﬁed as described elsewhere [27]( D i r e s se ta l .
unpublished data). The IFNs were then compared with the
EDQM reference standard (IFN-α 2 a ) .A ss h o w ni nF i g u r e6,
the deamidated and the oxidized samples behave similarly to
the reference standard (in fact it is very hard to distinguish
between the standard and the deamidated sample whileJournal of Biomedicine and Biotechnology 7
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Figure 5: Test ofthe stabilityofthe cell lines.Cells atthree diﬀerent stages(passage#15,46,51) were tested in thisvalidation,which involved
3 replicates for each dose and in 3 replicate plates. Sample 1 was the in-house reference standard (a), with sample #2 and #3 being ﬁnal drug
products from syringes (b,c). Each sample was run in triplicate and tested on 3 diﬀerent plates. The graphs represent the linear range of the
tested doses as determined by comparison to the international reference standard.
Table 2: Relative potency determination of IFN variants compared with the reference standards.
LL of estimated
potency∗
Estimated
potency∗
UL of estimated
potency∗
LL of relative
potency (%)
Relative potency
(%)#
UL of relativepotency
(%)
Oxidized 2655720 20936900 26468300 61.30 77.50 98.00
Deaminated 22397100 28327600 35830700 83.00 104.90 132.70
Aggregated 33793 58875 99115 0.10 0.220 0.4
∗:Actual reading of luciferaseactivity;
#:Relative potency compared withthe reference standards asdetermined by statisticalanalyses(bold face).The values in bold face referto therelative potency
of the samples with respect to the reference standards (EDQM IFN-α 2a). LL stands for lower limitsof the 95% interval while UL denotes upper limitsof the
95% interval.
we can notice a small diﬀerence between the standard and
the oxidized form). On the other hand, the aggregated form
shows no activity. Thus, these ﬁndings suggest no signiﬁcant
loss of potency with deamidated IFN while approximately
23% loss of potency was observed with the oxidized form.
In addition, the aggregated form completely lost its potency
(refer to Table 2). These results suggest that the RGA could
be further explored to analyze the potency of the variants.
3.6. Validation of RGA and Comparison with the AVA.
To validate the RGA, known amounts of IFN-β predeter-
mined by the routine AVA were spiked into the culture
media and subjected to the RGA for the determination of
potency in comparison with the reference standards. Three
expected potency ratios, (i.e., 80%, 100% and 120%) of
the internal standard concentrations were employed. As
s h o w ni nF i g u r e7, the dose response curves for the three8 Journal of Biomedicine and Biotechnology
Table 3: Relative potency of IFN-β as determined by RGA.
IFN-β samples (%) Mean estimated
potency
Relative to
assessment(%)
Lower and upper
limits (95% CI) (%)
80 25875.9 86.8% 79.4–94.9
100 32462.7 108.9% 99.6–119.1
120 34193.8 114.7% 104.9–125.5
The IFN-β samples were pre-determined by AVA, followed by spiking into media at 80, 100, and 120% of the expected values. The “spiked” samples were
then subjected to RGA analysesin comparison with the reference standards.
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Figure 6: Analyses of IFN variants. The variants (IFN-α 2a) were
prepared as described in [27] and (Diress et al. unpublished data).
The variants included aggregated, deamidated or oxidized forms.
The data showed that no signiﬁcant loss of potency was observed
with deamidated IFN while approximately 23% loss of potency was
observed with the oxidized form; moreover, the aggregated form
completely lost its bioactivity. Each sample was tested in triplicate
andpotency wasdetermined by comparisontotheEDQM IFN-α 2a
reference standard.
“spiked”IFN-βsamples satisfy 4-PLmodelassumptions (i.e.,
regression, linearity, and parallelism). Most importantly, the
concentrations of IFN-β yield the expected potency ratios of
0.8, 1.0, and 1.2, with very narrow 95% conﬁdence intervals
(Table 3). Experiments were then conducted to do a head-
to-head comparison between RGA and AVA with respect
to the detection range and variability. In this study, the
IFN-β was tested for 12 diﬀerent serial dilutions, with each
dose containing 6 replicates in three separate plates. We
found that both, AVA and RGA, satisﬁed the 4-PL model
assumptions (Figure 8). RGA displayed even better curve
ﬁt than AVA did. Moreover, within the replicates for each
concentration of the sample, RGA is much less variable than
AVA, as demonstrated by smaller CV% (1.89 versus 4.35).
Furthermore,itisworthmentioningthatwealsoinvestigated
the plate-to-plate variations, and the variations amongst
the three plates are not statistically diﬀerent between plates
(P = .32) although visual inspection of the results might
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Figure 7: Validation of the RGA. Known amounts of IFN-β pre-
determined by routine AVA were spiked into the culture media and
subjected to RGA. Three expected potency ratios of the internal
standard concentrations were employed, that is, 80%, 100%, and
120%. Samples were run as four replicates and potency was
determined by comparing to the in-house reference standard.
suggest that AVA (Figure 8(a) performs better than RGA
(Figure 8(b)). But the truth is that RGA has a much wider
detection range (0.24IU–1600IU) compared with the AVA
(0.098IU–100IU)andalsoshowslessheteroscedasticity,that
is, the OD values are less variable in response to lower and
higher concentrations of IFN (Figure 8). Taken together,
these data obtained from the above studies suggest that the
new method (RGA)has in general a betterperformance than
the traditional method (AVA).
4.Discussion
IFNs have been prescribed in the last few decades for
the treatment of infectious and autoimmune diseases and
selected types of cancer [8–11]. Accurate determination of
the potency of therapeutic IFNs is crucial for the safety
and eﬃcacy of the drug. It is of note that adverse reactions
caused by therapeutic interferon have been reported [35,
36]. Its potency is traditionally determined by AVAs, in
which the inhibitory activity of IFNs on viral replication in
cell cultures is measured. AVA is known to be a laborious
assay associated with poor reproducibility. It also requiresJournal of Biomedicine and Biotechnology 9
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Figure 8: Comparison between AVA and RGA. Panel (a) represents dose response curve from the AVA for the potency determination of
IFN-β1b. Panel (b) represents dose response curve from the RGA for the potency determination of IFN-β1b. For both methods, each dose
of the sample was analyzed in six replicates on three diﬀerent plates. Data shown here represents one of several repeated experiments.
maintenance of apermissive cell line,as well as manipulation
of the viruses in a biocontainment laboratory [14–17, 19,
20, 37–40]. Various bioassays used for interferon potency
determinations have been discussed [12, 13, 18]. Speciﬁcally,
several types of alternative potency assays for IFN have
been reported including antiproliferative assays, quantitative
reverse transcription polymerase chain reaction (qPCR) and
RGAs. The anti-proliferative assays appear to be less sensitive
than AVA, display marked variations between the diﬀerent
cell lines and require radio-isotope use in some cases [13].
Recently, some investigators reported the use of qPCR to
determine the potency of IFN through quantiﬁcation of
IFN-responsive genes [39, 40]. Moore et al. developed two
assays based on qPCR and cDNA for the measurements of
IFN bioactivity and adapted for the analyses of neutralizing
antibodies (NAbs) to type I IFN [38]. Alternative assays
based on quantiﬁcation of IFN-inducible gene products,
that is, IFN-responsive promoter-driven reporter gene, have
recently received great attention because of their simplicity,
rapidity and reproducibility. These RGAs employed a variety
of IFN responsive promoters including Mx, ISRE, GFAP
[16–26]. Using Mx2/Luc reporter cell line, Seo et al. [23]
reported the RGA is even more sensitive than the ISRE/Luc
reporter cell line. While previous studies have provided
strong evidences that RGA is advantageous compared to
the traditional AVA with respect to simplicity, rapidity and
reproducibility, optimization and/or modiﬁcation of the
RGAs also appear to be necessary since some systems are
associated with narrow detection range or require extra steps
after the addition of IFN. In addition, no RGAs have been
used to study the chemically modiﬁed IFNs, which could
potentially result in a loss of therapeutic eﬃcacy orincreased
immunogenicity of the therapeutic proteins [24–26, 29–
34]. In this communication, we studied the suitability of
HEK293 cells stably transfected with ISRE-driven luciferase
construct for the analyses of native and variant forms of IFN
and the validation of the assay in a wider biological and
statistical context. The choice of HEK293 is largely due to
the fact that HEK293 cells are of human origin [41], easy
to be cultured and reported to be suitable for human IFN
potencytesting[13–17].Indeed,theRGAdescribedhereisin
general agreement with previous RGAs, particularly with the
degree of variability (CV) [16–26]. Here we summarize our
observation in comparison with the data reported by others
in the literatures: (1) unlike most others, our validation of
the stability of the cell line exceeded more than 51 passages,
with no signiﬁcant diﬀerence found in cell line stability
even after 51 passages in relation to IFN responsiveness.
It is unclear to us how stable the other cell lines are
as most reports did not reveal data from studies on cell
stability beyond 51 passages except that of Smilovi´ ce ta l .
[22] who reported that the reporter gene/CHO cell line
was stable for over 1 year. (2) Assays based on luciferase
measurements like this one reported here are simpler than
reporter assays using CAT since luciferase-based RGAs do
not need ELISA to quantify CAT expression; noticeably,
SEAP-based RGAshavealso beenreported to belesssensitive
than RGAs based on luciferase; however, the SEAP substrate
(p-nitrophenylphosphate, NPP) may be directly added to
the wells [13]. (3) Our studies using RGA yielded some
interesting observations, speciﬁcally, the aggregated form of
IFN losses it’s activity, consistent with data from Caserman
et al. [19]; we also observed a modest loss of activity in
the oxidized form of IFN and a nearly “full” activity of10 Journal of Biomedicine and Biotechnology
deamidated IFN, suggesting that bioactivity measurement
may not be enough to identify the deamidated or oxidized
v a r i a n t s .F o rt h i sp u r p o s e ,w eh a v ed e v e l o p e dr e v e r s ep h a s e
HPLC and ion exchange HPLC to identify those variants
(Diress et al, manuscript in preparation). (4) Lastly, the
inclusion of four analysts and head-to-head comparison in
the validation studies revealed that although RGA is much
simpler, prior training for staﬀ who have never performed
luciferase assays is still recommended, given the relatively
larger CV% values found in those analysts (Figure 4). In our
experience however, RGA procedure enabled laboratory staﬀ
tobecomeproﬁcientinconductingRGAsmuchquickerthan
they do for the AVA. Our cell lines reported here would be
made available to any investigator who is interested in using
these stable cells for their own validation studies.
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